Grail EBITDA par action

Que fait Grail ? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail est l'une des entreprises les plus populaires sur Eulerpool.